Indian pharmaceutical company Hetero Drugs has received emergency use approval from the country's health authorities to make a generic version of Swiss healthcare company Roche Holding AG's (SWX:ROG.S) COVID-19 drug, tocilizumab, Reuters news agency reported on Monday.
Hetero expects to make tocilizumab available in India by the end of the month under the brand name Tocira.
It will reportedly be made by Hetero's unit at its Hyderabad facility.
Roche's arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Henlius and Sandoz expand biosimilars collaboration
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent